Hims & Hers Health is back at the center of Wall Street attention. After a turbulent start to 2026, the telehealth company has staged a sharp stock rebound, driven by a strategic pivot in its weight-loss business and a new agreement with Novo Nordisk. For investors, the story has quickly shifted from regulatory pressure and legal uncertainty to renewed questions about growth, margins, and the long-term economics of branded GLP-1 distribution.
The latest catalyst arrived on March 9, 2026, when Hims & Hers announced a strategic shift for its U.S. weight-loss business. The company said it would align its domestic model more closely with its international approach, focusing more heavily on FDA-approved GLP-1 treatments and reducing the visibility of compounded alternatives. At the center of that shift is a new collaboration with Novo Nordisk, which will bring Ozempic and Wegovy products to the Hims platform. The agreement also led Novo to dismiss its lawsuit against Hims & Hers without prejudice, removing a major overhang that had weighed on the stock.
That announcement triggered an explosive market reaction. Reuters reported that Hims shares surged more than 40% on March 9 after the Novo agreement became public, while earlier reports on March 6 had already sent the stock sharply higher in after-hours trading. The move marked one of the strongest single-day rallies in the company’s recent history and reflected relief that Hims had avoided a prolonged legal battle with one of the most powerful players in the obesity-drug market.
Why did investors respond so aggressively? Because the deal with Novo Nordisk changes the narrative in several ways at once. First, it reduces legal risk. Second, it lowers regulatory pressure at a moment when the U.S. Food and Drug Administration has intensified its crackdown on misleading marketing for compounded GLP-1 products. Third, it gives Hims a clearer path to stay relevant in weight loss even as regulators and pharmaceutical manufacturers push the market toward approved branded drugs. In short, the company has traded a high-risk gray zone for a more conventional, but potentially lower-margin, commercial model.
That distinction matters. For much of the recent bull-versus-bear debate around Hims & Hers, the central issue was not whether demand for weight-loss treatments existed, but whether Hims could sustainably monetize that demand through compounded semaglutide offerings. In February, the FDA said it intended to take decisive action against non-FDA-approved GLP-1 drugs and false or misleading marketing claims. Around the same time, Novo Nordisk escalated its dispute with Hims following the launch of a low-cost compounded weight-loss pill. Those developments raised serious concerns that one of Hims’ most exciting growth engines could face structural disruption.
The market clearly priced in those fears. On February 23, when Hims reported fourth-quarter and full-year 2025 results, the numbers themselves looked strong on the surface: full-year revenue rose 59% to roughly $2.35 billion, net income reached $128 million, adjusted EBITDA climbed to $318 million, and subscribers grew to more than 2.5 million. Fourth-quarter revenue came in at $617.8 million, up 28% year over year. Those are not the metrics of a company in retreat. Yet the stock came under pressure because first-quarter guidance disappointed investors and because management’s outlook highlighted the uncertainty surrounding the evolving GLP-1 landscape.
Specifically, Hims guided for first-quarter 2026 revenue of $600 million to $625 million, below analyst expectations cited by Reuters. While its full-year 2026 revenue guidance of $2.7 billion to $2.9 billion was broadly around market expectations, investors were unsettled by the near-term slowdown and by the prospect that regulatory changes could affect one of the company’s fastest-growing categories. Reuters noted that the company’s expected 2026 growth rate would slow sharply compared with the 59% expansion recorded in 2025. That contrast reinforced the idea that Hims was entering a more difficult phase, even before the latest strategic reset.
Management had already signaled that 2026 would be a transition year. In its earnings materials, Hims stated that its guidance assumed the ongoing ability to provide access to compounded semaglutide and no changes to existing business relationships. That caveat now looks especially important. Within just a few weeks, the company moved from defending its ability to operate in a more restrictive environment to formally reworking its U.S. weight-loss strategy around a broader assortment of FDA-approved medications. This is exactly why the stock has been so volatile: the underlying business opportunity remains large, but the rules governing how Hims can participate have been changing rapidly.
The new Novo partnership may solve one problem while creating another. By replacing a larger portion of its compounded GLP-1 proposition with branded products, Hims likely improves regulatory durability and brand credibility. But branded distribution may also come with lower gross profit economics than compounded alternatives. That is one reason some analysts remain cautious even after upgrading the stock. Barron’s reported that Citi and BofA both moved to less-bearish ratings after the deal, yet skepticism remains about whether subscription growth can accelerate enough to offset margin pressure and any revenue mix changes.
Investors should therefore think about Hims & Hers in two layers. The first layer is the short-term trading story. On that front, the stock has reacted violently to each major headline: enthusiasm over cheap weight-loss offerings, fear after FDA and legal scrutiny, disappointment after soft first-quarter guidance, and then euphoria after the Novo agreement. This pattern suggests HIMS remains a headline-sensitive momentum stock, especially because the weight-loss category has become the market’s primary lens for valuing the company.
The second layer is the longer-term platform story. Here, Hims still has a compelling case. The company has scaled to more than 2.5 million subscribers, increased monthly revenue per average subscriber, and expanded beyond its original categories into more personalized and higher-value care offerings. It is also pushing internationally. In February, Hims announced an agreement to acquire Eucalyptus, a move designed to accelerate its ambition to become a leading global consumer health platform. The company has also said it launched operations in the European Union and Canada during 2025 and deepened its presence in the United Kingdom.
For stock-market participants, valuation now depends on which version of Hims they believe in. The bullish view is that the Novo Nordisk deal validates Hims as a legitimate distribution and patient-acquisition platform for major drugmakers. It also suggests that Hims can survive the regulatory cleanup of the compounded GLP-1 market and continue monetizing obesity care at scale. The bearish view is that Hims has lost some pricing flexibility, faces margin compression, and may struggle to replicate the economics investors once hoped to see in the weight-loss business.
What seems clear is that March 2026 has become a turning point. The latest rally is not just another speculative spike; it reflects a material shift in business structure. Hims & Hers is no longer simply defending its place in weight loss. It is trying to redefine that place under tighter rules and with larger pharmaceutical partners. That may ultimately make the business more stable, even if the next few quarters remain noisy.
Conclusion
Hims & Hers has gone from regulatory target to strategic adapter in a matter of weeks. The company’s new collaboration with Novo Nordisk has reignited investor optimism, removed a legal overhang, and repositioned its U.S. weight-loss business around FDA-approved GLP-1 treatments. At the same time, recent earnings guidance and ongoing questions about margins show that the story is far from risk-free. For now, HIMS stock is trading on a mix of relief, momentum, and belief that the company can evolve from a controversial disruptor into a scaled digital healthcare platform.
FAQ
Why did Hims & Hers stock jump in March 2026?
The biggest trigger was the March 9 announcement of a collaboration with Novo Nordisk that will bring branded Ozempic and Wegovy products to the Hims platform and end, at least for now, Novo’s lawsuit against the company.
What happened after Hims & Hers earnings?
Although Hims reported strong 2025 growth, investors focused on weaker-than-expected first-quarter 2026 revenue guidance and uncertainty tied to the GLP-1 business, which pressured the stock after earnings.
Is Hims & Hers still offering compounded GLP-1 drugs?
The company said it will no longer advertise compounded GLP-1 offerings and plans to offer them only on a limited basis when a provider determines they are clinically necessary.
What is the latest Hims stock price?
At the time of this research, HIMS was trading around $23.47.
What is the biggest risk for Hims & Hers now?
The key risk is whether the shift toward FDA-approved branded GLP-1s can sustain growth without materially hurting margins and profitability. That remains the central debate around the stock.
Disclaimer
This article is for informational and editorial purposes only and does not constitute investment advice, financial advice, or a recommendation to buy or sell any security. Stock prices, company strategies, and regulatory conditions can change rapidly, and investors should review primary filings and consider their own risk tolerance before making investment decisions.
